Introduction
============

The *HER2* gene encodes a 185 kDa monomeric protein, which is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family.[@b1-ott-11-801] Approximately 25% of breast cancer (BC) patients present with *HER2* gene amplification,[@b1-ott-11-801] which is an independent prognostic factor of poor outcome. Anti-HER2 therapy is now a standard treatment for HER2-positive patients both in adjuvant and metastatic settings.[@b2-ott-11-801] When HER2-positive patients are treated with adjuvant trastuzumab therapy, the 10-year survival rate could be increased from 75.2% to 84%. Still, approximately 10% of these patients will inevitably develop recurrent or metastatic disease despite anti-HER2 treatment, reflecting the heterogeneous tumor biology of HER2-positive BC.[@b3-ott-11-801]

In addition to the well-acknowledged fact that HER2 expression status represents a poor prognosis and good response to trastuzumab, effective methods are still required to distinguish the tumor biology of HER2-positive BC. As a routinely conducted test, fluorescence in situ hybridization (FISH) provides a linear measurement for the *HER2* gene amplification level, which seems to be a promising figure in reflecting the nature of HER2-positive BC. Several studies were carried out referring to this issue in adjuvant, neoadjuvant, and metastatic settings. In adjuvant settings, a large sample study by Xuan et al[@b4-ott-11-801] observed an increased disease-free survival in trastuzumab-treated patients with a lower *HER2* amplification level. In addition, a study from Borley et al[@b5-ott-11-801] observed an increased progression-free survival and overall survival in patients with lower *HER2* gene copy number. However, research that was correlated to the HERA trial showed no obvious influence of the *HER2* amplification degree on patient prognosis.[@b6-ott-11-801] The latest meta-analysis from Xu et al[@b7-ott-11-801] denied any correlations between this figure and survival.

In late-stage BC, a study from Fuchs et al[@b8-ott-11-801] showed both higher *HER2* gene copy number (GCN) and that *HER2/CEP17* ratio is associated with shorter time to first metastasis in patients treated with trastuzumab and chemotherapy. Similarly another study also observed a shorter time to progression in patients with high *HER2/CEP17* ratio.[@b9-ott-11-801] However, there was another study that observed an opposite trend: patients with high-level *HER2/CEP17* ratio showed a longer progression-free survival.[@b10-ott-11-801]

In regard to neoadjuvant settings, results from different institutions were even more controversial.[@b11-ott-11-801]--[@b13-ott-11-801] It is still unclear whether *HER2* amplification level is correlated with patients' response to concurrent neoadjuvant therapy.

Disparity in the results may derive from the heterogeneity of patients and treatment in each study. Thus, we started to investigate this issue in the population of our prospective trials, in which patients received weekly paclitaxel in combination with cisplatin for neoadjuvant chemotherapy concurrent with trastuzumab in cases where the tumor was HER2-positive. In this study, we hypothesize that a higher *HER2/CEP17* ratio or *HER2* GCN is associated with more aggressive tumor biology and better pathological complete response (pCR) outcome in this highly uniform subset of patients.

Materials and methods
=====================

Patients and study design
-------------------------

BC patients from two paclitaxel- and cisplatin-based neoadjuvant clinical trials were included. The two trials were separately registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) as SHPD001 (NCT02199418) and SHPD002 (NCT02221999). SHPD001 was reviewed and approved by two independent ethical committees and institutional review boards of RenJi Hospital, Shanghai Jiao Tong University and Fudan University Shanghai Cancer Center. SHPD002 was reviewed and approved by the independent ethical committee and institutional review board of RenJi Hospital, Shanghai Jiao Tong University. All patients provided written informed consent.

Women aged ≥18 years old with histologically confirmed locally advanced invasive BC were included. For all patients, paclitaxel 80 mg/m^2^ was given weekly starting on day 1 for 16 weeks; cisplatin 25 mg/m^2^ was given weekly on day 1, 8, and 15 every 28 days for 4 cycles. For HER2-positive patients in SHPD001, trastuzumab was recommended concurrently. All HER2-positive patients in SHPD002 received concurrent trastuzumab. Trastuzumab was given at a loading dose of 4 mg/kg, followed by a maintenance dose of 2 mg/kg, on day 1 for 16 weeks. For hormone receptor-positive patients in SHPD002, endocrine therapy of aromatase inhibitor or gonadotropin-releasing hormone agonist was randomized together with chemotherapy according to the patient's menstrual status. Planned surgery was given sequentially after neoadjuvant chemotherapy. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

The study's primary outcome with regard to the two groups SHPD001 and SHPD002 was pCR, which was defined as the absence of tumor in the breast and axillary lymph nodes samples taken at the time of surgery.

Up until December 2016, 103 postoperative patients who went through the FISH test and 45 HER2-positive trastuzumab-treated patients were available for the analysis.

IHC and FISH
------------

ER, PR, and ki67 levels were assessed by immunohistochemistry (IHC) in paraffin-embedded tumor samples from biopsy. All patients enrolled in the clinical trial were tested by IHC to determine their HER2 status. Patients who tested 1+ to 3+ by IHC and some of the IHC 0 patients (n=103) were examined by FISH. FISH was carried out on paraffinized tissue sections using the *HER2* DNA Dual Probe Kit (Linked-Biotech Pathology, Guangzhou, People's Republic of China). HER2 positivity is defined according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) recommendations from 2013.[@b14-ott-11-801] In detail, 60 cells were routinely counted for FISH testing. Each cell was counted for *HER2* signal (red) and *CEP17* signal (green). Then, an average *HER2* signal per cell and an average *CEP17* signal per cell were used to obtain the final FISH ratio.

Both IHC and FISH assessment were conducted and confirmed by two qualified pathologists from the Department of Pathology, Shanghai Renji Hospital or Fudan University Shanghai Cancer Center.

Statistical methods
-------------------

Spearman's correlation test was used to determine the correlations between the *HER2* GCN, *HER2/CEP17* ratio, and other clinicopathological characteristics in patients who underwent FISH (n=103). In patients treated with concurrent trastuzumab (n=45), correlations between *HER2* GCN, the *HER2/CEP17* ratio, and pathological response to neoadjuvant therapy were calculated by both univariate and multivariate logistic regression analysis. Receiver operating characteristic (ROC) analysis was performed to see if *HER2* GCN and *HER2/CEP17* could independently predict patients' response to neoadjuvant therapy. Sensitivity and specificity were calculated to determine the optimal cutoff points. All statistical analyses were carried out using STATA Statistics SE 14 (Stata Corp LP, College Station, TX, USA). The results were considered significant when *p*\<0.05.

Results
=======

Correlations of *HER2* gene amplification level and other clinicopathological characteristics
---------------------------------------------------------------------------------------------

The baseline characteristics of all 103 patients who were available for FISH results to be obtained are shown in [Table 1](#t1-ott-11-801){ref-type="table"}. Among these patients, *HER2* GCN ranged from 1.45 to 65 and *HER2/CEP17* ratios ranged from 1.09 to 50. No polysomy 17 cases were reported. *HER2* GCN was inversely related to ER expression level (*p*\<0.001) and PR expression level (*p*\<0.001) and positively related to ki67 level (*p*=0.042); the *HER2/CEP17* ratio was also inversely related with ER expression level (*p*\<0.001) and PR expression level (*p*\<0.001) and positively related with tumor size (*p*=0.004). No significant correlations were found between age and the *HER2* amplification level in either the ratio or GCN group ([Table 2](#t2-ott-11-801){ref-type="table"}).

Baseline clinical characteristics of trastuzumab-treated patients and their response to chemotherapy concurrent with target therapy
-----------------------------------------------------------------------------------------------------------------------------------

Among the 45 patients who were HER2 positive and treated with trastuzumab, 22 patients reached pCR after surgery; the pCR rate was 48.9%. The baseline clinical characteristics of these 45 patients are summarized in [Table 3](#t3-ott-11-801){ref-type="table"}. The detailed relationship between the *HER2/CEP17* ratio, *HER2* GCN, and neoadjuvant outcome for each patient is displayed in [Figures 1](#f1-ott-11-801){ref-type="fig"} and [2](#f2-ott-11-801){ref-type="fig"}. An obvious increase in pCR outcome was observed when the *HER2/CEP17* ratio or *HER2* GCN was elevated.

Correlations of quantitative *HER2* gene amplification and pCR outcome
----------------------------------------------------------------------

In univariate analysis, both a higher HER2/CEP17 ratio (odds ratio \[OR\] =1.827, *p*=0.008; 95% confidence interval \[CI\]: 1.176--2.851) and HER2 GCN amplification level (OR =1.139, *p*=0.029; 95% CI: 1.013--1.230) were associated with a better pCR rate, while ER expression was associated with a poorer pCR rate (OR =0.211, *p*=0.025; 95% CI: 0.053--0.824).

Similarly, in multivariate analysis, a higher HER2/CEP17 ratio (OR =2.110, *p*=0.005; 95% CI: 1.266--3.861) was also associated with a better pCR rate, while ER expression was associated with a poorer pCR rate (OR =0.101, *p*=0.038; 95% CI: 0.012--0.884). HER2 GCN was also positively related to pCR (OR =1.147, *p*=0.050; 95% CI: 1.000--1.317) when adjusted. No significant correlations between other potential factors including patient age, PR status, and tumor size were observed ([Tables 4](#t4-ott-11-801){ref-type="table"}[](#t5-ott-11-801){ref-type="table"}--[6](#t6-ott-11-801){ref-type="table"}).

Optimal predictive cutoff points decided by ROC curve
-----------------------------------------------------

The optimal cutoff point determined by ROC analysis was 4.5 for the HER2/CEP17 ratio and 14 for HER2 GCN, which were expected to distinguish the most sensitive and specific candidates for cisplatin- and paclitaxel-based weekly neoadjuvant chemotherapy combined with trastuzumab. The area under the curve value of the HER2/CEP17 ratio was 0.786 compared with 0.656 of HER2 GCN ([Figure 3](#f3-ott-11-801){ref-type="fig"}).

Discussion
==========

HER2 gene amplification was associated with poor survival outcome in BC patients. It is also an indication of trastuzumab treatment in HER2-positive BC patients.[@b15-ott-11-801] However, the dosage effect of the HER2 gene amplification level on BC patients is not quite clear. Our study demonstrated that both HER2 GCN and HER2/CEP17 ratios are correlated with unfavorable prognostic factors. As for the predictive value, we demonstrated that both the HER2/CEP17 ratio and HER GCN were associated with better pCR outcome in trastuzumab-treated patients. This was the first time, at least to our knowledge, that correlations between tumor biology features, neoadjuvant treatment sensitivity, and both the HER2/CEP17 ratio and HER2 GCN were demonstrated in data from prospective clinical trials in the People's Republic of China.

We did FISH tests in patients with an IHC score equal to or greater than 0 at biopsy. This provided a more diverse population compared to studies conducted in patients who were mostly IHC 3+. In this set of patients, a higher *HER2* amplification level seemed to be accompanied by unfavorable clinicopathological factors. For instance, ER and PR status were inversely related to both *HER2* GCN and *HER2/CEP17* ratios. This result was supported by the work from Arnould et al.[@b11-ott-11-801] In that research, high amplification of *HER2* was correlated with hormone receptor-negative tumors.

With regard to predictive value, existing data from clinical trials and observations have already shown that tumors with higher proliferation and invasion potential were more sensitive to chemotherapy. For instance, triple-negative BC often exhibits an increased pCR rate but a decreased overall survival compared with other BC subtypes.[@b16-ott-11-801],[@b17-ott-11-801] Similar to triple-negative BC, a study from Yu et al[@b12-ott-11-801] demonstrated that HER2-positive BC was sensitive to neoadjuvant chemotherapy.[@b12-ott-11-801] All the patients in that study were HER2 positive and received neoadjuvant chemotherapy without targeted therapy. Yu et al observed a better pCR rate in patients with both higher *HER2/CEP17* ratio and *HER2* GCN.

Yu et al's study might indicate the sensitivity of patients with higher HER2 amplification level to chemotherapy. Our study demonstrated, as well, that these patients are more sensitive to targeted therapy.

Our results are partially supported by the studies from Arnould et al[@b11-ott-11-801] and Guiu et al,[@b15-ott-11-801] where patients received concurrent trastuzumab and neoadjuvant chemotherapy of different regimens. Those patients were originally tested IHC 3+ or 2+ for HER2 status. FISH assays were retrospectively conducted using the ASCO/CAP guideline version 2007.[@b23-ott-11-801] Only *HER2* GCN was analyzed. When *HER2* GCN =10 was used as the cutoff, the authors observed a better pCR rate in the cohort with high GCN. Our work is also supported by the work from Kogawa et al. Patients who received concurrent trastuzumab and neoadjuvant chemotherapy in that study showed a positive correlations between *HER2/CEP17* ratio and pCR.[@b18-ott-11-801]

On the other hand, the study from Buzdar et al[@b13-ott-11-801] showed no correlation between *HER2* amplification level and pCR outcome. However, only a brief conclusion was mentioned in the study. A detailed statistical method was not described.

Different from the neoadjuvant setting, results in the adjuvant settings are quite inconsistent. Briefly, we summarize some relevant studies in [Table 7](#t7-ott-11-801){ref-type="table"}. In adjuvant settings, studies from Xuan et al[@b4-ott-11-801] and Borley et al[@b5-ott-11-801] found a positive correlation between *HER2* GCN and survival, but studies from Perez et al[@b3-ott-11-801] and Dowsett et al[@b6-ott-11-801] found no correlation. The difference between settings might derive from the schedule of trastuzumab. In neoadjuvant settings, trastuzumab is often used concurrently with chemotherapy. But in the adjuvant setting, trastuzumab is usually used sequentially with chemotherapy. Concurrent chemotherapy and trastuzumab could increase the treatment effect, which might explain the major discrepancies between settings. Besides, the method of *HER2* signal counting might also influence the result. In the study from Perez et al, the maximum HER2 signal count for the form of clouds was assigned as 20 per cell. This approach would not change the decision for trastuzumab treatment, but could underestimate the amplification level of some patients.

The pharmacological mechanism of trastuzumab was reported mainly from two aspects. One was described as anti-HER2 dimerization and blockage of downstream cell signaling. The other was considered to be related to immune- and antibody-dependent cell-mediated cytotoxi-city (ADCC).[@b19-ott-11-801] When trastuzumab binds to the FCγR of natural killer cells, it would trigger ADCC and activate cell lysis. Some studies have reported that single-nucleotide polymorphisms of the FCγR might predict the efficacy of trastuzumab.[@b20-ott-11-801],[@b21-ott-11-801] One of the studies focused on the FCγR gene *FCGR3A* and determined that single-nucleotide polymorphism rs396991 changed the amino acid on position 158 of *FCGR3A*. Patients with the low-affinity allele received less benefit from trastuzumab. Theoretically, a higher *HER2* gene amplification level may lead to higher HER2 protein expression on the tumor cell surface. This is probably true considering the general consistency of the IHC and FISH results. At the same time, the tumor cell tends to combine with more antibodies, thus causing a greater extent of ADCC. Preclinical studies did determine that the ADCC effect of trastuzumab was partially relevant to HER2 expression levels on tumor target cells in BC patients.[@b22-ott-11-801] This was consistent with our result from the clinical samples.

Though the FISH result seemed simple and superficial, we should not neglect its value as a method for *HER2* gene quantization and as a therapeutic predictor. A highlight of our study is that we could use this routinely conducted test as a predictive and prognosis marker in HER2-positive patients, if validated.

Trastuzumab and pertuzumab are dual-targeted drugs for HER2-positive BC in the neoadjuvant setting. However, pertuzumab is not approved in the People's Republic of China currently. Thus, only trastuzumab was used in all the patients. Another major limitation of our study is the relatively small sample size. However, we did observe an obvious trend between the *HER2* amplification level and pCR results, despite the small sample size. Studies with larger sample sizes and assessing longer-term survival data are currently ongoing to validate our results in future studies.

Conclusion
==========

In summary, our study demonstrated that while using the latest ASCO/CAP guideline for HER2 testing, a higher *HER2* amplification level was correlated with larger tumor size and less ER and PR expression. In addition, both a higher *HER2/CEP17* ratio and *HER2* GCN could predict a better response to neoadjuvant therapy in trastuzumab-treated HER2-positive patients from neoadjuvant trials.
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![HER2/CEP17 ratio and neoadjuvant outcome of 44 patients treated with trastuzumab.\
**Notes:** Every column represents an individual patient with an HER2/CEP17 ratio value (x-axis). The blue column represents pCR outcome, yellow column represents non-pCR outcome. An increasing tendency for pCR outcome was observed when the HER2/CEP17 ratio was elevated. One patient was not shown in the figure because the HER2/CEP17 value was too big (50).\
**Abbreviation:** pCR, pathological complete response.](ott-11-801Fig1){#f1-ott-11-801}

![*HER2* GCN and neoadjuvant outcome of 44 patients treated with trastuzumab.\
**Notes:** Every column represents an individual patient with an *HER2* GCN value (x-axis). The blue column represents pCR outcome, yellow column represents non-pCR outcome. An increasing tendency for pCR outcome was observed when *HER2* GCN was elevated.\
**Abbreviations:** GCN, gene copy number; pCR, pathological complete response.](ott-11-801Fig2){#f2-ott-11-801}

![Optimal cutoff points of *HER2/CEP17* ratio and HER2 GCN decided by ROC curves.\
**Notes:** ROC curve using *HER2/CEP17* ratio (**A**) and *HER2* GCN (**B**) to select the best responder to concurrent neoadjuvant chemotherapy and trastuzumab. The AUC for HER2/CEP17 ratio was 0.786, which was better than the AUC for *HER2* GCN (0.656).\
**Abbreviations:** GCN, gene copy number; ROC, receiver operating characteristic; AUC, area under the curve.](ott-11-801Fig3){#f3-ott-11-801}

###### 

Baseline clinical characteristics of all patients

  Characteristics                                         Number (n)   Percentage (%)
  ------------------------------------------------------- ------------ ----------------
  Age (years)                                                          
   ≥50                                                    59           57
   \<50                                                   44           43
  Tumor size                                                           
   \>5 cm                                                 58           56
   ≤5 cm                                                  44           44
  ER status                                                            
   ER +                                                   78           76
   ER −                                                   25           24
  PR status                                                            
   PR +                                                   85           83
   PR −                                                   18           17
  ki67 status[a](#tfn1-ott-11-801){ref-type="table-fn"}                
   \>30%                                                  59           57
   ≤30%                                                   44           43
  Menopause status                                                     
   Pre                                                    51           50
   Post                                                   52           50

**Note:**

Most of the patients had a ki67 level greater than 14%, and thus 30% was used to separate the groups.

###### 

Correlations between *HER2* amplification level and clinicopathological characteristics of all patients

  Characteristics     N[a](#tfn2-ott-11-801){ref-type="table-fn"}   *p*-value (HER2 GCN)[b](#tfn3-ott-11-801){ref-type="table-fn"}   N     *p*-value (HER2/CEP17 ratio)
  ------------------- --------------------------------------------- ---------------------------------------------------------------- ----- ------------------------------
  Age                 101                                           0.051                                                            103   0.465
  Tumor size          100                                           0.194                                                            102   **0.004**
  ER status           101                                           **0.000**                                                        103   **0.000**
  PR status           101                                           **0.000**                                                        103   **0.000**
  Menopausal status   101                                           0.057                                                            103   0.372
  ki67                101                                           **0.042**                                                        103   0.154

**Notes:**

101 patients had values for *HER2* GCN;

Bold facing indicates statistical significance.

**Abbreviation:** GCN, gene copy number.

###### 

Baseline clinical characteristics of HER2-positive trastuzumab-treated patients

  Characteristics    Number (n)   Percentage (%)
  ------------------ ------------ ----------------
  Age (years)                     
   ≥50               26           58
   \<50              19           42
  Tumor size                      
   \>5 cm            30           67
   ≤5 cm             15           33
  ER status                       
   ER +              30           67
   ER −              15           33
  PR status                       
   PR +              33           73
   PR −              12           7
  ki67 status                     
   \>30%             30           67
   ≤30%              15           33
  Menopause status                
   Pre               21           47
   Post              24           53

###### 

Univariate analyses for predictive factors of HER2-positive trastuzumab-treated patients

  Characteristics                Univariate analysis                                                    
  ------------------------------ ---------------------------------------------- ------- ------- ------- -----------
  *HER2* GCN                     44[a](#tfn5-ott-11-801){ref-type="table-fn"}   1.139   1.013   1.230   **0.029**
  *HER2/CEP17* ratio             45                                             1.827   1.170   2.851   **0.008**
  Age (years) ≥50 vs \<50        45                                             2.338   0.694   7.872   0.170
  ER positive vs negative        45                                             0.211   0.053   0.824   **0.025**
  PR positive vs negative        45                                             0.368   0.092   1.471   0.158
  Tumor size (cm) \>5 vs ≤5      45                                             0.680   0.219   2.108   0.504
  Menopause status pre vs post   45                                             1.576   0.484   5.126   0.450
  ki67                           45                                             1.028   0.994   1.063   0.105

**Notes:**

44 patients had values for *HER2* GCN;

Bold facing indicates statistical significance.

**Abbreviations:** OR, odds ratio; CI, confidence interval; GCN, gene copy number.

###### 

Multivariate analyses for predictive factors of pCR using *HER2/CEP17* ratio

  Characteristics             Multivariate analysis                           
  --------------------------- ----------------------- ------- ------- ------- -----------
  *HER2/CEP17* ratio          45                      2.210   1.266   3.861   **0.005**
  Age (years) ≥50 vs \<50     45                      0.962   0.167   5.560   0.966
  ER positive vs negative     45                      0.078   0.009   0.673   **0.020**
  PR positive vs negative     45                      1.192   0.187   7.585   0.852
  Tumor size (cm) \>5 vs ≤5   45                      0.719   0.480   1.077   0.110

**Note:**

Bold facing indicates statistical significance.

**Abbreviations:** pCR, pathological complete response; OR, odds ratio; CI, confidence interval.

###### 

Multivariate analysis for predictive factors of pCR using *HER2* GCN

  Characteristics             Multivariate analysis                           
  --------------------------- ----------------------- ------- ------- ------- -----------
  *HER2* GCN                  44                      1.147   1.000   1.317   **0.050**
  Age (years) ≥50 vs \<50     44                      0.609   0.117   3.176   0.556
  ER positive vs negative     44                      0.190   0.343   1.046   0.056
  PR positive vs negative     44                      0.560   0.125   2.723   0.473
  Tumor size (cm) \>5 vs ≤5   44                      0.881   0.654   1.186   0.404

**Notes:**

44 patients had values for *HER2* GCN;

Bold facing indicates statistical significance.

**Abbreviations:** pCR, pathological complete response; GCN, gene copy number; OR, odds ratio; CI, confidence interval.

###### 

Summary of the relevant research

  Study                                  Settings      Treatment                                                                                                                    Testing method        Conclusion
  -------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------- -------------------------------------------------------------------------
  Borley et al,[@b5-ott-11-801] 2014     Adjuvant      Adjuvant therapy (details not provided)                                                                                      FISH (dual probe)     High *HER2* GCN associated with better survival
  Xuan et al,[@b4-ott-11-801] 2015                     Trastuzumab-based chemotherapy                                                                                               FISH (dual probe)     Both GCN and *HER2/CEP17* ratio (RATIO) associated with better survival
  Perez et al,[@b3-ott-11-801] 2014                    Doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab                                              FISH (dual probe)     No correlations between survival and RATIO/GCN
  Dowsett et al,[@b6-ott-11-801] 2009                  Chemotherapy followed by trastuzumab                                                                                         FISH (dual probe)     No correlations between survival and RATIO/GCN
  Arnould et al,[@b11-ott-11-801] 2007   Neoadjuvant   Trastuzumab-based chemotherapy with either docetaxel or docetaxel plus carboplatin                                           FISH (single probe)   High GCN associated with pCR
  Buzdar et al,[@b13-ott-11-801] 2007                  Trastuzumab-based chemotherapy with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide                   FISH (dual probe)     No correlations between pCR and RATIO/GCN
  Kogawa et al,[@b18-ott-11-801] 2016                  Chemotherapy with an anthracycline and/or a taxane given in combination or sequential regimens with or without trastuzumab   FISH (dual probe)     High RATIO associated with pCR
  Yu et al,[@b12-ott-11-801] 2012                      Chemotherapy without trastuzumab                                                                                             FISH (dual probe)     High GCN associated with pCR
  Fuchs et al,[@b8-ott-11-801] 2014      Metastatic    Trastuzumab-based treatment                                                                                                  FISH (dual probe)     High GCN associated with shorter time to first metastasis
  Gullo et al,[@b9-ott-11-801] 2009                    Trastuzumab-based treatment                                                                                                  FISH (dual probe)     High RATIO associated with shorter TTP
  Kim et al,[@b10-ott-11-801] 2013                     Trastuzumab plus taxane chemotherapy                                                                                         FISH (dual probe)     High RATIO associated with longer PFS

**Abbreviations:** FISH, fluorescence in situ hybridization; GCN, gene copy number; pCR, pathological complete response; TTP, time to progression; PFS, progression- free survival.
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